NCT04781855 2025-02-28Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter TransformationM.D. Anderson Cancer CenterPhase 1 Withdrawn
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT01769222 2024-01-24Ipilimumab and Local Radiation for Selected Solid TumorsStanford UniversityPhase 1 Terminated3 enrolled 5 charts